Today: 17 May 2026
Lockheed Martin Gets Golden Dome Shot as $3.2 Billion Space Shield Race Opens
26 April 2026
2 mins read

Lockheed Martin Gets Golden Dome Shot as $3.2 Billion Space Shield Race Opens

Washington, April 26, 2026, 09:01 EDT

  • Lockheed Martin landed a spot among those chosen for U.S. Space Force prototype efforts related to Golden Dome.
  • The awards follow a softer quarter, as profit and cash flow took a hit from production setbacks and fixed-price charges.
  • SpaceX, Northrop Grumman, and Anduril are among several others vying for the same prize.

Lockheed Martin Corporation now joins the latest wave of Washington’s Golden Dome missile-defense initiative. The U.S. Space Force has listed the company among those eligible for prototype contracts totaling up to $3.2 billion. The project focuses on developing space-based interceptors—orbital weapons meant to target missiles earlier in their flight—with a first demonstration set for 2028.

Timing is crucial here. Lockheed wants to turn robust demand for its missiles, aircraft, and space systems into more consistent profits, especially after first-quarter earnings took a hit from production setbacks and contract overruns. Those Space Force awards add more names to the field—SpaceX, Northrop Grumman, and Anduril—giving the Pentagon extra flexibility to juggle suppliers as the contract moves from drawing board to actual hardware.

U.S. markets didn’t open Sunday. Lockheed shares finished Friday at $513.45, down 3.08%, as investors continued digesting a quarterly report highlighting weaker aeronautics and cash flow figures.

Space Systems Command handed out 20 Other Transaction Authority agreements to a dozen firms. OTAs let the Pentagon sidestep the usual procurement process—speeding things up and opening the door to suppliers outside the defense establishment. “Acquisition strategies must move even faster,” Col. Bryon McClain, program executive officer for Space Combat Power, said, pointing to increasingly nimble missile threats. SSC

Golden Dome’s expected price tag lands at roughly $185 billion, with plans to bolster current ground-based missile defenses by incorporating space systems, Reuters reported. The Space Force, for its part, has said it wants the interceptor program folded into the broader Golden Dome setup by 2028. Technical specifics, though, remain scarce—the service is holding those details back for operational security reasons.

Lockheed’s most recent numbers highlight why the new award is a plus, but not a cure-all for investors. First-quarter sales landed at $18.0 billion, with net earnings at $1.5 billion. Free cash flow, after capital outlays, came in at negative $291 million. The company stuck to its 2026 guidance.

Lockheed CEO Jim Taiclet said the company has reached framework agreements aimed at ramping up munitions output, covering advanced Patriot missiles, THAAD, and PrSM. According to Taiclet, these deals could boost production to “3-4 times current rates”—a significant goal as the Pentagon leans on defense firms to turn out hardware faster, not just lock in larger contracts. Media – Lockheed Martin

Still, the main challenge comes down to execution. According to Reuters, Lockheed’s quarterly profit took a hit from expensive fixed-price contracts and slower production. Delays on the F-16 program and problems sourcing C-130 parts dragged on the company’s aeronautics unit. With fixed-price deals, when supplier costs rise beyond projections, margins get squeezed.

Lockheed skipped buybacks this quarter, responding to pressure from Washington to channel funds into boosting production. “We aren’t surprised,” said JPMorgan’s Seth Seifman, who pointed to management’s push to stay in step with what customers want. Reuters

Policy tailwinds look strong. Reuters reported the Trump administration’s fiscal 2027 defense budget calls for boosting F-35 purchases to 85 jets per year and lists Golden Dome as a “presidential priority.” That positions Lockheed to benefit from both missile defense and fighter sales—even as it deals with lingering delays in some legacy programs. Reuters

The upside isn’t locked in yet. Golden Dome is in a prototype sprint, and future contracts might end up with competitors if their solutions outperform or undercut on price. Lockheed’s challenge now is straightforward: show it can deliver what Washington wants, on schedule and without squeezing margins.

Stock Market Today

  • Bipartisan Support for CLARITY Act Boosts Bitcoin and XRP in May
    May 16, 2026, 7:02 PM EDT. The CLARITY Act, which recently passed the Senate Banking Committee 15-9 with bipartisan support, sparked immediate gains in Bitcoin and XRP. Bitcoin surged to nearly $81,500, while XRP broke through $1.45 resistance briefly hitting $1.50. Historically, Bitcoin prices have rallied following significant regulatory milestones, including ETF approvals and government reserves, reaching highs of $126,000. XRP's performance is notably sensitive to regulatory clarity, exemplified by gains after an SEC ruling and classification as a digital commodity. If the CLARITY Act continues its momentum toward a Senate floor vote, both cryptocurrencies could experience further price appreciation by month-end, though Bitcoin and XRP are expected to move at different paces.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
Meta vs Google vs Apple Stock Price Forecast: Big Tech Earnings Week Could Shift the AI Trade
Previous Story

Meta vs Google vs Apple Stock Price Forecast: Big Tech Earnings Week Could Shift the AI Trade

Cameco Corporation Stock Slips Before Q1 Results — Why Uranium Investors Are Watching May 5
Next Story

Cameco Corporation Stock Slips Before Q1 Results — Why Uranium Investors Are Watching May 5

Go toTop